How Long Does FDA 510(k) Clearance Take for AI Devices? 2025 Data

Planning your regulatory timeline is one of the most consequential decisions in AI medical device development. Underestimate and you burn runway. Overestimate and you lose competitive ground. The problem is that most timeline estimates come from regulatory consultants quoting general 510(k) statistics that don't reflect the AI-specific landscape.

This post uses AIFDA Intel's analysis of 950+ cleared AI and ML devices to give you real numbers — by indication, product code, and submission type.

The Overall Picture

The median 510(k) review time for AI medical devices is approximately 9.1 months from submission to clearance. That's meaningfully longer than the FDA's reported overall 510(k) median of around 6-7 months. The gap reflects the additional questions FDA reviewers raise about AI-specific issues: algorithm performance, training data, generalizability, and drift monitoring.

But the median hides enormous variation. The 25th percentile is 6.2 months. The 75th percentile is 14.3 months. If your submission has issues — deficiencies, additional information requests, panel referrals — you're looking at the high end of that range.

Review Times by Indication

Radiology AI (QMF, OZO, MRZ)

Radiology AI is the most-reviewed category and has the most established regulatory precedent. Median review time: 8.4 months. FDA reviewers are familiar with the performance metrics, the predicate landscape is rich, and special controls are well-defined. This is the most predictable category for timeline planning.

Cardiology AI (QFP, PWF)

Cardiac AI has median review times of approximately 8.8 months. ECG and rhythm analysis AI tends to be faster; echocardiography AI, which involves more complex image interpretation, tends to take longer. Panel referrals are more common in cardiology.

Pathology AI (PIE)

Digital pathology AI is one of the longer categories — median approximately 11 months. FDA has been deliberate about establishing standards for whole-slide image analysis, and reviewers frequently request additional clinical validation data. The category is still maturing.

Ophthalmology AI (PZB, OWJ)

Retinal imaging AI has a median of approximately 9.3 months. Autonomous diagnostic AI (OWJ) takes considerably longer — often 14+ months — because of the heightened scrutiny applied to devices that make diagnostic decisions without clinician review.

Neurology AI (OYP)

Neurological AI has median review times around 10.5 months, reflecting the complexity of the clinical questions involved and the relative immaturity of the predicate landscape.

Sepsis/ICU AI (QBS)

This is a new category established in 2024. Insufficient data to calculate a reliable median, but early indications suggest 10-14 months given the high-acuity clinical setting and FDA's focus on real-world performance validation.

What Drives Longer Reviews

Based on analysis of Additional Information (AI) requests in cleared submissions, the most common reasons AI device reviews take longer:

• Insufficient diversity in training and test datasets — FDA increasingly expects demographic and site diversity
• Vague claims about algorithm performance — "improved sensitivity" without a defined comparator
• Missing standalone performance data — FDA wants to see the algorithm tested independently, not just as part of a workflow study
• Unclear software change control — not describing how algorithm updates will be managed post-clearance
• No PCCP or inadequate PCCP — increasingly, reviewers ask about algorithm change protocols upfront

Submission Type Matters

Traditional 510(k) submissions for AI devices take a median of 9.1 months. Abbreviated 510(k)s — where you rely on recognized consensus standards — can be faster, around 7-8 months. Special 510(k)s, for modifications to already-cleared devices, average around 5-6 months when the modification is well-characterized.

If you have a PCCP in place, algorithm updates that fall within the plan's scope don't require a new submission at all — which is why PCCP planning upfront can dramatically change your post-market timeline calculus.

The Pre-Submission Meeting Impact

One of the clearest patterns in the data: submissions with a documented pre-submission (Q-sub) meeting with FDA tend to clear faster than those without, particularly in novel or complex indications. A Q-sub adds 2-3 months upfront but often saves 4-6 months of deficiency cycles later. For first-in-category submissions, it's almost always worth it.

Planning Your Timeline

For planning purposes, we recommend:

• Use the 75th percentile (14 months) as your conservative estimate for fundraising and board planning
• Use the median (9 months) as your base case for operational planning
• Budget for one Additional Information request — this is the norm, not the exception
• Add 2-3 months if you're in a novel indication without close predicates
• Subtract 1-2 months if you have a strong, recent predicate in the same product code